We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-32.69%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$110M
AUM Growth
-$58.1M
Cap. Flow
+$4.12M
Cap. Flow %
3.75%
Top 10 Hldgs %
94.25%
Holding
17
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$9.09M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$2.29M
2
CBAY
Cymabay Therapeutics
CBAY
+$1.36M
3
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.77B
$33.5M 30.41%
1,171,268
-65,934
-5% -$2.29M
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$28M 25.42%
219,901
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$8.12M 7.38%
901,943
– –
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$7.98M 7.25%
+311,285
New +$9.09M
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.1M 5.54%
2,080,595
– –
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.57M 5.06%
440,000
– –
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.34M 4.85%
1,041,131
– –
TARA icon
8
Protara Therapeutics
TARA
$230M
$4.58M 4.16%
50,447
– –
AUPH icon
9
Aurinia Pharmaceuticals
AUPH
$2.01B
$2.72M 2.47%
400,434
– –
SRRA
10
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.89M 1.72%
36,111
– –
CLLS
11
Cellectis
CLLS
$276M
$1.66M 1.51%
100,000
– –
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$2.81B
$1.66M 1.5%
38,100
– –
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
$1.44M 1.31%
250,000
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$1.03M 0.94%
131,036
-142,381
-52% -$1.36M
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$458K 0.42%
352,300
– –
OCGN icon
16
Ocugen
OCGN
$454M
$77K 0.07%
14,815
– –
AVEO
17
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-40,000
Closed -$1.32M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2018 Portfolio in Review

As of Q4 2018, Abingworth held 17 positions worth $110M, down 35% from $168M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Abingworth deployed $4.12M of net new capital in Q4 2018, opening 1 new position. Its largest new stake was Soleno Therapeutics: 311,285 shares worth $7.98M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was CRISPR Therapeutics, an estimated $2.29M trimmed.

  • Abingworth's largest Q4 2018 buy was Soleno Therapeutics: 311,285 shares worth $7.98M.
  • Abingworth's biggest Q4 2018 reduction was CRISPR Therapeutics, cutting an estimated $2.29M.
  • Abingworth fully exited AVEO Pharmaceuticals, Inc. in Q4 2018, selling an estimated $1.32M.
  • Abingworth's ten largest holdings make up 94% of its $110M portfolio in Q4 2018.
  • Abingworth opened 1 new position and closed 1 in Q4 2018.
  • Abingworth's portfolio value fell 35% quarter-over-quarter to $110M.

Based on Abingworth's 13F filing for Q4 2018, filed 14 Feb 2019.